Functional Dyspepsia Clinical Trial
Official title:
Synergistic Gut-brain Axis Modulation Via Vagal Stimulation and Cognitive Behavioral Therapy in Functional Dyspepsia
The primary aims of this randomized, single-blinded, 2x2 sham-controlled trial are to 1) evaluate synergistic impact of 8-weeks of transcutaneous auricular vagus nerve stimulation (taVNS) + cognitive-behavioral therapy (CBT) on post-meal gut-brain communication; 2) determine the sequential relationship between treatment-associated changes in gastrointestinal-related anxiety and both clinical functional dyspepsia (FD) improvements and meal-induced physiological outcomes; 3) investigate whether post-treatment changes in gut-brain physiology mediate improvements in FD clinical outcomes. Using a fully non-invasive framework including gastric and brain magnetic resonance imaging (MRI) and taVNS, the investigators aim to evaluate the potential synergy of taVNS and CBT in FD, by assessing the gut-brain physiological response to prandial challenge, linking physiological with symptom improvements.
Status | Not yet recruiting |
Enrollment | 80 |
Est. completion date | March 2029 |
Est. primary completion date | March 2029 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: Age 18-65 years old (inclusive) - Ability to give written consent and participate in behavioral intervention in English - Willingness to attend weekly treatment sessions over live video, daily self-administered transcutaneous auricular vagus nerve stimulation (taVNS) sessions, and engage in homework during treatment - Avoidance of alcohol, nicotine, and caffeine for 24 hours prior to study session - Diagnosis according to the Rome IV criteria for both epigastric pain syndrome and postprandial distress syndrome subtypes - Stable medical treatment for functional dyspepsia (FD) during 1 month before the study and during the study period Exclusion Criteria: - Previous receipt of cognitive behavioral therapy (CBT) for gastrointestinal symptoms - Enteral or parenteral feeding - Previous gastrointestinal surgery, electrolyte disturbances, kidney dysfunction, renal insufficiency, or iron overload disorders - Estimated Glomerular Filtration Rate (eGFR) < 60 - Medications that affect gastrointestinal motility in addition to medications or products containing tetrahydrocannabinol (THC) will be stopped at least 7 days prior to the start of the study and for the duration of the study. However, anti-depressants (SSRI's, TCA's) may be allowed in order to reduce the risk of worsening neuropsychiatric disease, though it will be up to the study team and the Principal Investigator whether subjects on anti-depressants will be able to participate in the study - Intellectual disability by history - Diabetes, mitochondrial disease, severe autonomic dysfunction, and small fiber polyneuropathy - No active clinical acupuncture therapy - Illicit drugs or opioid usage - History of arrhythmias - Current pregnancy/breastfeeding - Contraindications for magnetic resonance imaging (MRI) (implanted ferromagnetic objects, claustrophobia) - Weight > 450 lbs. (limit of the MRI table) - Allergy to pineapple (used in the test meal during MRI) - Any other condition interfering with study requirements, according to the Investigator |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Spaulding Rehabilitation Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Nepean Dyspepsia Index (NDI) | FD symptoms severity; score ranging from 0 to 100, with higher scores indicating worse outcomes | 8 weeks (post-treatment) | |
Primary | Visceral Sensitivity Index (VSI) | GI-related anxiety; score ranging from score ranging from 0 to 75, with higher scores indicating worse outcomes | 8 weeks (post-treatment) | |
Secondary | Gastric peristaltic velocity | MRI-derived gastric motility outcome | 8 weeks (post-treatment) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04464369 -
Functional Dyspepsia: Validation of the Leuven Postprandial Distress Scale (LPDS) in a Placebo-controlled Trial
|
Phase 4 | |
Completed |
NCT01671670 -
Acupuncture for Patients With Function Dyspepsia
|
Phase 2/Phase 3 | |
Completed |
NCT00987805 -
Efficacy of Banhasasim-tang on Functional Dyspepsia
|
Phase 4 | |
Completed |
NCT00693407 -
Study of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation
|
N/A | |
Completed |
NCT00761358 -
To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia
|
Phase 3 | |
Recruiting |
NCT01240096 -
Mirtazapine Versus Placebo in Functional Dyspepsia
|
Phase 4 | |
Recruiting |
NCT04540549 -
Effects of Exercise on Functional Dyspepsia Based on Rome IV
|
N/A | |
Recruiting |
NCT03652571 -
Nortriptyline for the Treatment of Functional Dyspepsia
|
Phase 3 | |
Recruiting |
NCT06068114 -
Gastric Pathophysiology in Diabetes
|
||
Recruiting |
NCT03825692 -
International Clinical Study of Zhizhu Kuanzhong Capsule
|
Phase 4 | |
Not yet recruiting |
NCT04548011 -
Acupuncture of Different Treatment Frequency on Improving Quality of Life in Patients With Functional Dyspepsia
|
N/A | |
Terminated |
NCT02567578 -
A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
|
Phase 2 | |
Completed |
NCT03007433 -
Assessment of GI Function to a Large Test Meal by Non-invasive Imaging
|
N/A | |
Active, not recruiting |
NCT00990405 -
Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia
|
Phase 4 | |
Completed |
NCT00404534 -
Helicobacter Eradication Relief of Dyspeptic Symptoms
|
Phase 3 | |
Completed |
NCT03043625 -
Visceral Manipulation Treatment to Patients With Non-specific Neck Pain With Functional Dyspepsia
|
N/A | |
Completed |
NCT03225248 -
Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia
|
Phase 3 | |
Recruiting |
NCT05587127 -
Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia
|
N/A | |
Recruiting |
NCT01021475 -
Does Visceral Manipulation Works in Treating Functional Dyspepsia?
|
Phase 1 |